HYBRID EVENT: You can participate in person at Paris, France or Virtually from your home or work.

6th Edition of World Congress on Infectious Diseases

June 24-26, 2024 | Paris, France

June 24 -26, 2024 | Paris, France
Infection 2024

De chu Christopher Tang

Speaker at Infection Conference - De chu Christopher Tang
VaxDome Inc., United States
Title : Virus/mutation-agnostic vaccines


Respiratory RNA viruses often mutate into new variants with subsets ravaging public health as escape mutants that render contemporary vaccines and antivirals ineffective from time to time. We have serendipitously developed an innovative approach to vaccine development against respiratory viruses. Our initial research demonstrated that a virulent influenza virus (IFV) could be easily transformed into an influenza vaccine by incubating IFV with an excessive amount of zanamivir in vitro. This new approach has the advantage that the vaccine also acts as a virus/mutation-agnostic antiviral as well as a vaccine potentiator in one package. We demonstrated that intranasal administration of the zanamivir-crippled IFV A/Puerto Rico/8/34 (PR8) dubbed zPR8 elicited adaptive immune responses against PR8 as a safe influenza vaccine. In addition, zPR8 conferred rapid but transient protection of mice against lethal challenges by the mouse coronavirus (CoV) MHV1 in an adaptive immunity-independent manner as a virus/mutation-agnostic antiviral. No appreciable production of interferon-alpha within the lung was induced by zPR8 itself post-administration; however, zPR8 inexplicably amplified CoV-induced interferon responses as an interferon multiplier. zPR8 also converted a lethal dose of CoV into a safe vaccine against repeat CoV infections as a vaccine potentiator. It is conceivable that the development of a modular system with a variety of influenza viruses disabled by a variety of neuraminidase inhibitors (NAI-IFV) capable of converting a myriad of villain viruses into safe vaccines as vaccine potentiators may enable rapid generation of vaccines in response to a surge of unknown viruses away from a Sisyphean cycle that requires characterization of unknown viral mutations that never end.


Dr. Tang and his associates were the first to have developed DNA vaccines, skin-patch vaccines, adenovirus-vectored in ovo vaccines, and virus/mutation-agnostic vaccines, etc. Dr. Tang obtained his PhD degree from Indiana University, and carried out his postdoctoral work at Baylor College of Medicine and Duke University. He was appointed as Assistant Instructor/Instructor at University of Texas Southwestern Medical Center, and subsequently as Assistant/Associate Professor at University of Alabama at Birmingham (UAB). He founded Vaxin Inc. (currently known as Altimmune, Inc.; Nasdaq: ALT) on UAB campus in 1997. He founded VaxDome Inc. in Fort Worth, Texas in 2019.